samotolisib

Samotolisib is an orally bioavailable small molecule dual inhibitor of class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR), acting within the PI3K/mTOR signaling pathway. It also inhibits DNA-dependent protein kinase (DNA-PK). By targeting these kinases in an ATP-competitive manner, samotolisib disrupts cancer cell proliferation and survival by blocking a pathway frequently upregulated in tumors. This mechanism may provide greater potency than agents inhibiting only PI3K or mTOR alone. Samotolisib has been investigated for various solid tumors including breast cancer, endometrial cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer, colon cancer, and advanced cancers. The drug was developed by Eli Lilly and Company; its highest clinical development phase reached was Phase II before discontinuation for all major indications[1][2][5].

Other names

1386874-06-1Samotolisib [USAN]